MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-18-2026
XOMA Corporation Cash and Cash Equivalents 2011-2026 | XOMA
Annual Cash and Cash Equivalents XOMA Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.9 M | 102 M | 153 M | 57.8 M | 93.3 M | 84.2 M | 56.7 M | 45.8 M | 43.5 M | 25.7 M | 65.8 M | 78.4 M | 102 M | 45.3 M | 48.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 153 M | 25.7 M | 72.3 M |
Quarterly Cash and Cash Equivalents XOMA Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.2 M | 75.1 M | 90.3 M | 102 M | 147 M | 150 M | 142 M | 153 M | 33.5 M | 31.4 M | 44.3 M | 57.8 M | 78.3 M | 83.2 M | 88.6 M | 93.3 M | 72.2 M | 78.9 M | 67.8 M | 84.2 M | 84.2 M | 84.2 M | 84.2 M | 56.7 M | 56.7 M | 56.7 M | 56.7 M | 45.8 M | 28.4 M | 38.7 M | 42 M | 43.5 M | 43.5 M | 43.5 M | 43.5 M | 25.7 M | 25.7 M | 25.7 M | 25.7 M | 65.8 M | 65.8 M | 65.8 M | 65.8 M | 78.4 M | 78.4 M | 78.4 M | 78.4 M | 102 M | 102 M | 102 M | 102 M | 45.3 M | 45.3 M | 45.3 M | 45.3 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 153 M | 25.7 M | 67.6 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aquestive Therapeutics
AQST
|
121 M | $ 4.16 | 1.46 % | $ 445 M |  USA |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
172 M | $ 9.77 | 1.82 % | $ 632 M | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 5.15 | 4.46 % | $ 793 M |  Britain |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
BioNTech SE
BNTX
|
7.68 B | $ 98.14 | -5.13 % | $ 27.2 B | Germany |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
320 M | $ 22.15 | -1.36 % | $ 3.67 B | USA |
 |
Athira Pharma
ATHA
|
69.3 M | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B | Britain |
 |
Cerus Corporation
CERS
|
20 M | $ 2.79 | 37.44 % | $ 532 M | USA |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
59.5 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
207 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | USA |
 |
Caladrius Biosciences
CLBS
|
16.2 M | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
50.7 M | - | - | $ 231 M | USA |
 |
Cardiff Oncology
CRDF
|
17.5 M | $ 1.72 | -0.87 % | $ 115 M | USA |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
29 K | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
83.5 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Innate Pharma S.A.
IPHA
|
28.1 M | $ 1.49 | 3.12 % | $ 235 M | France |
 |
Dynavax Technologies Corporation
DVAX
|
95.9 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 2.93 | -8.15 % | $ 4.82 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
25.4 M | - | -9.21 % | $ 2.55 M | USA |
 |
Editas Medicine
EDIT
|
147 M | $ 2.9 | -3.48 % | $ 257 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
19.2 M | - | -5.68 % | $ 8.28 M | USA |
 |
Edesa Biotech
EDSA
|
1 M | $ 17.81 | -2.57 % | $ 56.9 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
49.9 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |